Researchers have discovered that a low dose of the opioid antagonist naltrexone (LDN) can have an extraordinarily potent antitumor effect on human ovarian cancer in tissue culture.
The discovery provides new insights into the pathogenesis and treatment of ovarian neoplasia, which is the 4th leading cause of cancer-related mortality among U.S. women. The strategy of using LDN therapy to repress cancer was first reported over 30 years ago. Naltrexone causes an elevation in your body's own opioids and opioid receptors.
"Blockade of opioid peptides from opioid receptors for a short time each day (4 to 6 hr) with LDN provides a sufficient window of time (18-20 hr) for the elevated levels of endogenous opioids and opioid receptors to interact and elicit a response: inhibition of cell proliferation. Thus, LDN acts as a decoy to upregulate native opioids and opioid receptors."